Global Blepharitis Treatment Market Size showed crucial growth in the recent years and is anticipated to witness a steep rise by generating an estimated revenue of US$ xx.xx billion over the forecast period. According to latest study conducted by our analysts and industry experts, the global market is expected to grow at a CAGR of 6.7% during the forecast period, i.e. 2017-2025. Blepharitis is a condition characterized by reddening, crusting, irritation and inflammation of the eyelid. Blepharitis can be caused due to a number of reasons ranging from allergies to tear film irregularities, but the most common reasons of blepharitis are scalp dandruff (due to abnormal oil secretion in the eyelids) and bacterial infection.

Global Blepharitis Treatment Market Size, Share Analysis By Region 2017

This global market study report analysis offers in-depth insights, revenue details, and other vital information regarding the global blepharitis treatment market, and the various trends, drivers, restraints, opportunities, and threats in the target market till 2025. The report offers insightful and detailed information regarding the various key players operating in the market, their financials, supply chain trends, technological innovations, key developments, apart from future strategies, acquisitions & mergers, and market footprint. The global blepharitis treatment market report has been segmented on the basis of type, application, and region. It includes the estimation of the market size, in terms of value, with respect to 4 main geographies, namely, North America, Europe, APAC, and RoW.

Market Dynamics

Global blepharitis treatment market size is expected to grow significantly over the forecast period, owing to escalation in the prevalence of ophthalmological diseases such as staphylococcal infection and meibomian gland dysfunction(dry eye), which ultimately result in blepharitis. Increasing geriatric population is resulting in the increase in number of patients with eye related problems, which is expected to boost the growth of blepharitis treatment market. According to the United Nations, the number of older persons aging 80 years and above is expected to rise to 425 million in 2050 from 137 million in 2017. Furthermore, increased focus on novel drugs launch and their commercialization is aiding the growth of blepharitis treatment market. For instance, in May 2018, Grafton Optical, an UK-based ophthalmic instruments supplier announced the launch of its I-LID’N LASH, which is an ocular hygiene product designed for enhancing the treatment regimens for blepharitis (dry eye). However, high cost of blepharitis treatment drugs, eye cleansers, and other medication, coupled with lack of awareness towards the severity of blepharitis can hinder the growth of the global blepharitis treatment market size. 

Segment Analysis

Anterior blepharitis is expected to hold the major revenue share in the global blepharitis treatment market size over the forecast period, as it is the most common type of blepharitis affecting the growing geriatric population. According to Optometrists and Dispensing Opticians Board (ODOB), demodex infestation which increases along with age is a major cause for the occurrence of anterior blepharitis among population. As per ODOB, 84% population aged over 60 years and 100% aged over 70 years show demodex infestation.

Among treatment options, eye cleansers followed by ointments are expected to grow significantly over the forecast period as they are pain-free and affordable. Hygiene being an important factor that aids in the treatment of blepharitis is escalating the demand for eye cleansers such as LidHygenix cleanser (BlephEx). Oral antibodies are projected to grow rapidly over the forecast period due to increase in number of clinical trials on the drugs manufactured for the treatment of blepharitis, coupled with escalation in approval of novel drugs such as lifitegrast from regulatory bodies.

Among distribution channel, pharmacies followed by online channels are expected to show significant growth due to ease of purchase and availability of a number of treatment options such as ointments, antibiotics, and eye cleansers. Discount offered by online channels and presence of treatment products from a number of manufacturers provides patients with ample of choices to choose the best treatment option as per their necessity and budget.

Regional Analysis

The global blepharitis treatment market is divided into regions that are North America - U.S, Canada, Other) (Asia-Pacific -India, Japan, China, Australia, Other) (Europe - UK, Russia, France, Brazil, Other) (Middle East and Africa. Every region analysis details in sense of growth, revenue, volume, challenges, and opportunities with the regional and global key players.  North America is expected to hold the major revenue share in the global blepharitis treatment market over the forecast period, owing to rising geriatric population in the region. According to Population Reference Bureau (PRB), the number of Americans ageing 65 years and above is anticipated to reach 98 million by 2060. Rising awareness towards eye health in North America, coupled with governmental initiatives to reduce eye diseases are expected to boost the growth of blepharitis treatment market in the region. Europe is anticipated to rise significantly over the forecast period, due to presence of prominent market players and increase in the number of drugs for blepharitis in pipeline. Rising geriatric population in Europe is another major factor for the growth of blepharitis treatment market in the region.

Key Players

Key companies operating in global blepharitis treatment market include Lux Biosciences, Merck & Co., Novartis AG, Thea Pharmaceuticals Ltd., NovaBay Pharmaceuticals Inc., Scope Opthalmics Ltd., InSite Vision Incorporated, Gelderma S.A., and Perrigo Laboratories. Market players are focusing on merger and acquisition activities to commercialize the newly developed drugs at international platforms. For instance, in September 2017, Nicox, a French Pharmaceutical company, announced that it has entered into a licensing agreement with Eyevance Pharmaceuticals for the commercialization of ZERVIATE (an ophthalmic solution for treating ocular irritation and itching in eyes) in the U.S.

Global Blepharitis Treatment Market Study Report Offer You!

The global market study report gives an idea about market size, share, stock, equity, investment and total price analysis. Also, the report provides comprehensively industry insights with all major factors such as market credit, allocation, demand, distribution, market scope, key players, end user & applications, provisions, livestock, commodities and industry economics analysis, future growth & forecast. The global market report includes all depth data like pre-market emphasis, market survey, market investment, industry advice, portfolio, finance, access, trade, market exploration, industry review and market predication & projection to develop effective strategies for optimizing their market position.